Daiichi Sankyo announces commencement of clinical trials in Japan for Duchenne muscular dystrophy treatment
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that administration of the Duchenne muscular dystrophy (hereafter, DMD) treatment drug DS-5141b (hereafter, the Drug), which is jointly developing with the Orphan Disease Treatment Institute Co., Ltd. (hereafter, ODTI), to the first subject has begun in the first clinical trial in Japan.
Johnson & Johnson issues call for innovative ideas to reduce HIV infections in Sub-Saharan Africa
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) issued a call for innovative ideas as part of the DREAMS Innovation Challenge, which is supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and ViiV Healthcare.
Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children
- Details
- Category: GlaxoSmithKline
GSK and Save the Children today revealed the winners of their third annual US$1 million Healthcare Innovation Award, which recognises innovations from developing countries that are helping to reduce deaths among children under five.
Novartis shareholders approve all resolutions proposed by Board of Directors
- Details
- Category: Novartis
More than 97% of Novartis shareholders today followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting. A total of 1,776 shareholders were present at the meeting held in Basel, representing approximately 61.6% of the issued shares of Novartis.
Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced sale of its HIV R&D portfolio to ViiV Healthcare, which includes a number of programs at different stages of discovery, preclinical and clinical development.
Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack
- Details
- Category: AstraZeneca
AstraZeneca today announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
- Details
- Category: Novartis
Alcon, the global leader in eye care and a division of Novartis, announced today that it has entered into an agreement to acquire Transcend Medical, Inc., a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma.
More Pharma News ...
- U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis
- Bristol-Myers Squibb and Dana-Farber Cancer Institute enter into a collaboration agreement
- UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration
- Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
- Bayer continues to grow its open innovation activities
- Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction
- Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals